UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000008473 |
|---|---|
| Receipt number | R000009965 |
| Scientific Title | Phase II study of cetuximab with mFOLFOX6 therapy in patients with KRAS wild-type advanced colorectal cancer which has unresectable liver metastases |
| Date of disclosure of the study information | 2012/07/23 |
| Last modified on | 2020/01/28 15:57:05 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Phase II study of cetuximab with mFOLFOX6 therapy in patients with KRAS wild-type advanced colorectal cancer which has unresectable liver metastases
Acronym
Cmab mFOLFOX6 study
Scientific Title
Phase II study of cetuximab with mFOLFOX6 therapy in patients with KRAS wild-type advanced colorectal cancer which has unresectable liver metastases
Scientific Title:Acronym
Cmab mFOLFOX6 study
Region
| Japan |
Condition
Condition
colorectal cancer
Classification by specialty
| Gastroenterology | Gastrointestinal surgery |
Classification by malignancy
Malignancy
Genomic information
YES
Objectives
Narrative objectives1
To evaluate antitumor effect, safety and efficacy of cetuximab with mFOLFOX6 therapy inpatients with KRAS wild-type advanced colorectal cancer which has unrecectable liver metastasis
Basic objectives2
Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Confirmatory
Trial characteristics_2
Pragmatic
Developmental phase
Phase II
Assessment
Primary outcomes
Response rate
Key secondary outcomes
Safety
Resection rate of liver metastatis resion
R0 liver resection rate
Relapse-free survival
Overall survival
Treatment completion rate
Base
Study type
Interventional
Study design
Basic design
Single arm
Randomization
Non-randomized
Randomization unit
Blinding
Open -no one is blinded
Control
Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
1
Purpose of intervention
Treatment
Type of intervention
| Medicine |
Interventions/Control_1
The initial dosage of Cetuximab assumes it 400mg/ m2.
Cetuximab gives the second one week after initial administration, but the dose from the second assumes it 250mg/ m2.
mFOLFOX6 repeats the administration once in two weeks to up to six courses as 1 course.
Cetuximab is given in day 1 and day 8 all over the course of mFOLFOX6.
Perform hepatectomy four weeks later from the next day on a chemotherapy end day in case of resectable at the end of chemotherapy of 6 curses.
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
1)Colorectal cancer histological proven
2)Unresectable liver metastasis more than 5 synchronism liver metastases or more than 5cm tumor size
3)Primary tumor is performed radical excision of; or the case that is available for radical excision in curative hepatectomy by this study and synchronism or heterochrony
4)KRAS wild type of Codon 12 and codon 13
5)A measurable lesion or an evaluable lesion is confirmed with an objectivity document according to RECIST standard
6)No prior chemotherapy for colorectal cancer
7)No prior oxaliplatin and cetuximab or panitumumab
8)More than 20 years old
9)Expect to survive more than 3 months
10)ECOG performance status: 0-1
11)Organs (bone marrow, lung, liver and kidney) failure is not advanced
i)Hemoglobin : more than 8.0g/dl
ii)Neutrophil count : more than 1,500 / mm3
iii)Platelet : more than 100,000 / mm3
iv)Serum total bilirubin : less than 1.5 mg / dl
v)AST,ALT : less than 200 U/l
vi)Serum creatinine : less tahn 1.5 mg / dl
12)ECG no abnormalities in 28 days before
13)Informed consent
Key exclusion criteria
1)Severe drug allergy
2)Metastatic focus out of the liver
3)Active double cancer
4)Active infection
5)Intestinal paralysis, intestinal obstruction
6)Severe complications (interstitial pneumonia or pulmonary fibrosis, heart failure, kidney failure, liver failure, it is difficult to control hypertention, diabetes etc.)
7)Pleural effusion, ascites
8)Diarrhea (watery stool)
9)Brain metastases
10)Pregnant and lacting women
11)A bleeding tendency, coagulation disorder or the case with the abnormal clotting factor
12)Mental disorder
13)Patients who receive steroid continuously are excluded
14)Patients who have past histories of cerebral infarction, cardiac infarction and / or pulmonary infarction are excluded
15)History of the organ transplantation to need an immunosuppressive drug
16)The patient that a study responsibility physician judged to be inappropriat
Target sample size
23
Research contact person
Name of lead principal investigator
| 1st name | Ayumu |
| Middle name | |
| Last name | Goto MD. PhD. |
Organization
Yokohama City University Hospital
Division name
Clinical Oncology division
Zip code
236-0004
Address
3-9 Fukuura, Kanazawa-ku, Yokohama City, 236-0004, Japan
TEL
045-787-2800
ayumu16g@yokohama-cu.ac.jp
Public contact
Name of contact person
| 1st name | Ayumu |
| Middle name | |
| Last name | Goto MD. PhD. |
Organization
Yokohama City University Hospital
Division name
Clinical Oncology division
Zip code
232-0004
Address
3-9 Fukuura, Kanazawa-ku, Yokohama City, 236-0004, Japan
TEL
045-787-2800
Homepage URL
ayumu16g@yokohama-cu.ac.jp
Sponsor or person
Institute
Yokohama City University Hospital Clinical Oncology division
Institute
Department
Personal name
Funding Source
Organization
None
Organization
Division
Category of Funding Organization
Self funding
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Yokohama City University Ethics Committee
Address
3-9 Fukuura, Kanazawa-ku, Yokohama City, 236-0004, Japan
Tel
0453707627
rinri@yokohama-cu.ac.jp
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
横浜市立大学附属病院（神奈川県）
横浜市立大学附属市民総合医療センター（神奈川県）
横浜市立市民病院（神奈川県）
伊東市民病院（静岡県）
横浜掖済会病院（神奈川県）
横浜市済生会南部病院（神奈川県）
済生会若草病院（神奈川県）
横浜船員保険保険病院（神奈川県）
藤沢市民病院（神奈川県）
横須賀共済病院（神奈川県）
横須賀市立市民病院（神奈川県）
独立行政法人国立病院機構横浜医療センター（神奈川県）
横浜市立みなと赤十字病院（神奈川県）
Other administrative information
Date of disclosure of the study information
| 2012 | Year | 07 | Month | 23 | Day |
Related information
URL releasing protocol
NONE
Publication of results
Unpublished
Result
URL related to results and publications
NONE
Number of participants that the trial has enrolled
7
Results
early termination of clinical trial because of less saple size
Results date posted
| 2020 | Year | 01 | Month | 28 | Day |
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
single arm phase II trial of mFOLFOX6 plus cetuximab for colorectal cancer patients with liver metastasis
Participant flow
Single arm phase II (no randomaization)
Adverse events
No severe adverse events
Outcome measures
This single arm hase II trial has Simon Two-Stage design (Optimal design)
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Terminated
Date of protocol fixation
| 2011 | Year | 10 | Month | 13 | Day |
Date of IRB
| 2011 | Year | 11 | Month | 10 | Day |
Anticipated trial start date
| 2012 | Year | 07 | Month | 23 | Day |
Last follow-up date
| 2018 | Year | 01 | Month | 01 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2012 | Year | 07 | Month | 19 | Day |
Last modified on
| 2020 | Year | 01 | Month | 28 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000009965
